On Friday, Editas Medicine Inc (NASDAQ: EDIT) was -0.29% drop from the session before settling in for the closing price of $3.49. A 52-week range for EDIT has been $3.37 – $11.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 101.57%. When this article was written, the company’s average yearly earnings per share was at -44.10%. With a float of $81.70 million, this company’s outstanding shares have now reached $81.77 million.
Let’s determine the extent of company efficiency that accounts for 265 employees.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Editas Medicine Inc stocks. The insider ownership of Editas Medicine Inc is 0.94%, while institutional ownership is 69.56%. The most recent insider transaction that took place on Sep 04 ’24, was worth 1,774. In this transaction EVP, CHIEF MEDICAL OFFICER of this company sold 518 shares at a rate of $3.42, taking the stock ownership to the 133,895 shares. Before that another transaction happened on Sep 04 ’24, when Company’s CEO sold 1,555 for $3.42, making the entire transaction worth $5,325. This insider now owns 313,724 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -44.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
You can see what Editas Medicine Inc (EDIT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.36, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 1.96 million, which is a jump from its year-to-date volume of 1.91 million. As of the previous 9 days, the stock’s Stochastic %D was 11.11%. Additionally, its Average True Range was 0.22.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 3.31%, which indicates a significant decrease from 14.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.92% in the past 14 days, which was lower than the 70.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.17, while its 200-day Moving Average is $6.37. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $3.60. Second resistance stands at $3.72. The third major resistance level sits at $3.80. If the price goes on to break the first support level at $3.39, it is likely to go to the next support level at $3.31. Now, if the price goes above the second support level, the third support stands at $3.19.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are 82,238K outstanding shares of the company, which has a market capitalization of 287.03 million. As of now, sales total 78,120 K while income totals -153,220 K. Its latest quarter income was 510 K while its last quarter net income were -67,610 K.
